• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pulmonary Arterial Hypertension - Pipeline Review, H1 2012 Product Image

Pulmonary Arterial Hypertension - Pipeline Review, H1 2012

  • Published: April 2012
  • 117 pages
  • Global Markets Direct

Pulmonary Arterial Hypertension – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2012', provides an overview of the Pulmonary Arterial Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Arterial Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension. 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pulmonary Arterial Hypertension.
- A review READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pulmonary Arterial Hypertension Overview
Therapeutics Development
An Overview of Pipeline Products for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Therapeutics under Development by Companies
Pulmonary Arterial Hypertension Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Pulmonary Arterial Hypertension Therapeutics – Products under Development by Companies
Pulmonary Arterial Hypertension Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Pulmonary Arterial Hypertension Therapeutics Development
United Therapeutics Corporation
Mochida Pharmaceutical Co., Ltd.
Novartis AG
Actelion Ltd
Dong-A Pharmaceutical Co., Ltd.
Nippon Shinyaku Co., Ltd.
Bayer AG
NicOx SA
Arena Pharmaceuticals, Inc.
Proteo, Inc.
Aires Pharmaceuticals, Inc.
Cardioxyl Pharmaceuticals, Inc.
Asahi Kasei Pharma
Lacer, S.A.
Ikaria Inc.
Pulmonary Arterial Hypertension – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Aviptadil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tasigna - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY63-2521 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APD811 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QTI571 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Macitentan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-877 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UT-15C SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Beraprost Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Elafin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Based Gene Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LA-419 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MD-0701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carvedilol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Selexipag - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Milrinone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Warfarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vardenafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Y-Secretase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexmedetomidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dichloroacetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Reserpine + Fluoxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glutamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TXA127 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tracleer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IK-3001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zydena - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sildenafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AIR001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sildenafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eplerenone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nitroxyl Donor For PAH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NanoActive Sildenafil Citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCX 226 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anastrozole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pulmonary Arterial Hypertension Therapeutics – Drug Profile Updates
Pulmonary Arterial Hypertension Therapeutics – Discontinued Products
Pulmonary Arterial Hypertension Therapeutics - Dormant Products
Pulmonary Arterial Hypertension – Product Development Milestones
Featured News & Press Releases
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Ventavis
Feb 21, 2012: Oral Treprostinil New Drug Application Accepted For Review By FDA
Feb 06, 2012: United Therapeutics Receives Paragraph IV Notice Letter For Remodulin
Jan 23, 2012: Ikaria Receives Orphan Drug Designation From FDA For Use Of Inhaled Nitric Oxide In Pulmonary Arterial Hypertension
Dec 27, 2011: United Therapeutics Receives French Regulatory Approval For Intravenous Remodulin For Treatment Of Pulmonary Arterial Hypertension
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program
Sep 27, 2011: Tarix’s TXA127 Receives Orphan Drug Status For Treatment Of Pulmonary Arterial Hypertension
Sep 25, 2011: Novartis's Phase III Study Shows QTI571 Significantly Improves Walking Distance In Patients With Pulmonary Arterial Hypertension
Aug 24, 2011: United Therapeutics Announces Completion Of Phase III Trial of Oral Treprostinil In Pulmonary Arterial Hypertension
Jul 12, 2011: Arena Reports Phase I Results Of APD811 In Pulmonary Arterial Hypertension
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Pulmonary Arterial Hypertension, H1 2012
Products under Development for Pulmonary Arterial Hypertension – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
United Therapeutics Corporation, H1 2012
Mochida Pharmaceutical Co., Ltd., H1 2012
Novartis AG, H1 2012
Actelion Ltd, H1 2012
Dong-A Pharmaceutical Co., Ltd., H1 2012
Nippon Shinyaku Co., Ltd., H1 2012
Bayer AG, H1 2012
NicOx SA, H1 2012
Arena Pharmaceuticals, Inc., H1 2012
Proteo, Inc., H1 2012
Aires Pharmaceuticals, Inc., H1 2012
Cardioxyl Pharmaceuticals, Inc., H1 2012
Asahi Kasei Pharma, H1 2012
Lacer, S.A., H1 2012
Ikaria Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Pulmonary Arterial Hypertension Therapeutics – Drug Profile Updates
Pulmonary Arterial Hypertension Therapeutics – Discontinued Products
Pulmonary Arterial Hypertension Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Pulmonary Arterial Hypertension, H1 2012
Products under Development for Pulmonary Arterial Hypertension – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos